Overview
Royalty Pharma
?
Pablo Legorreta
See more contacts
Securities and Commodity Contracts Intermediation and Brokerage
,
Pharmaceutical and Medicine Manufacturing
,
Securities, Commodity Contracts, and Other Financial Investments and Related Activities
,
Finance and Insurance
,
Security brokers and dealers
See All Industries Pharmaceutical preparations
See Fewer Industries
See All Industries Pharmaceutical preparations
See Fewer Industries
Activities Related to Credit Intermediation
,
Agencies, Brokerages, and Other Insurance Related Activities
,
Depository Credit Intermediation
,
Insurance Carriers
,
Insurance and Employee Benefit Funds
,
Monetary Authorities-Central Bank
,
Nondepository Credit Intermediation
,
Other Financial Investment Activities
View more , Other Investment Pools and Funds Securities and Commodity Exchanges
View fewer
View more , Other Investment Pools and Funds Securities and Commodity Exchanges
View fewer
?
?
?
Modelled
?
Actual
$2.26 billion
Actual
-3.86%
-24.31%
$18,222
DEC
?
NASDAQ:RPRX
Contacts
Get in Touch with 5 Principals* and 68 Contacts
-
Pablo LegorretaChairman of the Board and Chief Executive Officer
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$2.26 billion
USD
Actual
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | $2,769 | $2,988 | $2,144 |
| Net Investing Cash | -$2,678 | -$2,073 | -$1,029 |
| Net Financing Cash | $361 | -$2,149 | -$945 |
| Net Change in Cash | $452 | -$1,234 | $170 |
| Cash at Beginning of Period | $477 | $1,711 | $1,541 |
| Cash at End of Period | $929 | $477 | $1,711 |
| Capital Expenditure | $ | $ | $ |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $929 | $477 | $1,711 |
| Accounts Receivable | $ | $ | $ |
| Inventories | $ | $ | $ |
| Other Current Assets | $873 | $797 | $844 |
| Asset Summary | |||
| Total Current Assets | $1,802 | $1,274 | $2,555 |
| Tangible Fixed Assets | $ | $ | $ |
| Intangible Assets | $ | $ | $ |
| Total Assets | $18,223 | $16,382 | $16,813 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $13 | $15 | $8 |
| Short-Term Debt | $998 | $ | $998 |
| Other Current Liabilities | $242 | $146 | $161 |
| Liability Summary | |||
| Total Current Liabilities | $1,254 | $161 | $1,167 |
| Long-Term Debt | $6,615 | $6,135 | $6,119 |
| Other Long-Term Liabilities | $12 | $1 | $2 |
| Total Liabilities | $7,880 | $6,298 | $7,288 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $0 | $0 | $0 |
| Retained Earnings | $2,846 | $2,518 | $1,965 |
| Equity Summary | |||
| Total Equity | $6,947 | $6,526 | $5,628 |
| Shares Outstanding | 445,985,000 | 446,692,000 | 443,166,000 |